Home>Topics>Stocks>Acorda Therapeutics

Acorda Therapeutics ACOR

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Acorda Therapeutics' ( ACOR ) CEO Ron Cohen on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Sat, 2 Aug 2014

      Acorda Therapeutics , Inc. (NASDAQ: ACOR ) Q2 2014 Results Earnings Conference Call July 31, 2014 ..... Chen – Aegis Capital Presentation Operator Welcome to the Acorda Therapeutics Second Quarter 2014 Financial Results Conference Call

    2. More on Acorda Q2 results

      Headlines

      Thu, 31 Jul 2014

      Acorda Therapeutics (NASDAQ: ACOR ) Q2 results : Net Revenues: $97.1M (+11.5%); Operating Expenses: $86.2M (+10.1%); Operating Income: $11

    3. Acorda Therapeutics beats on revenue

      Headlines

      Thu, 31 Jul 2014

      Acorda Therapeutics (NASDAQ: ACOR ): Q2 EPS of $0.42 Revenue of $97.13M (+11.6% Y/Y) beats by $5.73M . Press Release Post your comment!

    4. Notable earnings before Thursday’s open

      Headlines

      Wed, 30 Jul 2014

      AAWW , ABMD , ACIW , ACOR , ADP , AGI , ALKS , ALU , AMRC , APA , ASEI , ATK , AVP , AYR , AZN , BDX , BG , BGCP , BKCC , BLL , BUD , BWA , BZH , CCJ , CDW

    5. We're Boosting Biogen Idec's Fair Value Estimate Following European Approval of Fampyra

      Commentary

      Wed, 27 Jul 2011

      this week. Fampyra, which is marketed in the United States under the trade name Ampyra by the firm's partner Acorda Therapeutics ACOR , is the first approved treatment to improve walking in patients with multiple sclerosis. Fampyra now marks

    6. Acorda shares soar on possible patent extension

      Headlines

      Thu, 14 Apr 2011

      BOSTON (Reuters) - Shares of Acorda Therapeutics Inc jumped 27 percent on Thursday before being halted amid optimism the company will be granted a patent extension on its multiple sclerosis drug...

    7. Elan's 2010 Results In Line; Enthusiasm for Growth Potential Tempered by High-Risk Pipeline

      Commentary

      Tue, 8 Feb 2011

      EDT) were flat, as patent expirations on older products countered strong manufacturing and royalty revenue from Ampyra, Acorda and Biogen-Idec's BIIB new oral MS drug. Tysabri's net new-patient adds actually fell in the fourth quarter, as compared

    8. Tysabri Carries Elan in 2Q

      Commentary

      Thu, 22 Jul 2010

      exploring the possible sale of this business. Royalties on Acorda 's ACOR recently approved multiple sclerosis drug Ampyra will be key to EDT's future growth, and Acorda 's second-quarter results in August will give us a

    9. New Morningstar Analyst Report - Biogen Idec, Inc.

      Stock Reports

      Tue, 30 Mar 2010

      research and development pipeline to support long - term growth . We're most optimistic about the potential of Ampyra ; Acorda ACOR received FDA approval for the novel MS drug in January , and Biogen has acquired international rights . We think Biogen

    10. Biogen to Benefit From Reduced Tysabri Uncertainty

      Commentary

      Tue, 9 Feb 2010

      reduce the probability of a worst-case outcome in our scenario-weighted fair value estimate as a result. Acorda Therapeutics ACOR received FDA approval of Ampyra in January, and Biogen also filed for European approval of the drug last month

    « Prev12Next »
    Content Partners